References
- Cuenca EM, Bernal ML, Buitrago MJ, et al. Update on the epidemiology and diagnosis of invasive fungal infection. Int J Antimicmb Agents 2008;32(2):143-7. https://doi.org/10.1016/S0924-8579(08)70016-5
- Berking S, Doedens D, Horns H, et al. Antifungal prophylaxis in newly diagnosed AML patients adherence to guidelines and feasibility in a real life setting. Mycoses 2017;60(9):600-6. https://doi.org/10.1111/myc.12635
- Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356(4):348-59. https://doi.org/10.1056/NEJMoa061094
- Jung DS, Tverdek FP, Kontoyiannis DP, et al. Switching from Posaconazole Suspension to Tablets Increases Serum Drug Levels in Leukemia Patients without Clinically Relevant Hepatotoxicity. Antimicrob Agents Chemother 2014;58(11):6993-5. https://doi.org/10.1128/AAC.04035-14
- Durani U, Tosh PK, Barreto JN, et al. Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension. Antimicrob Agents Chemother 2015; 59(8):4914-8. https://doi.org/10.1128/AAC.00496-15
- Bruggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009;48(10):1441- 58. https://doi.org/10.1086/598327
- Krishna G, Moton A, Ma L, et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009;53(3):958-66. https://doi.org/10.1128/AAC.01034-08
- Doring M, Muller C, Johann PD, et al. Analysis of Posaconazole as Oral Antifungal Prophylaxis in Pediatric Patients Under 12 Years of Age Following Allogeneic Stem Cell Transplantation. BMC Infect Dis 2012;12:263. https://doi.org/10.1186/1471-2334-12-263
- De PB, Walsh TJ, Donnelly JP, et al. European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooper- ative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ MSG) Consensus Group (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46(12):1813-21. https://doi.org/10.1086/588660
- Lass-Florl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 2009;52(3):197-205. https://doi.org/10.1111/j.1439-0507.2009.01691.x
- Kung HC, Kan LP, Lin HA, et al. Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients. Cancer Medicine 2014;3(3):667-73. https://doi.org/10.1002/cam4.225
- Cho SH, Lee DG, Choi SM, et al. Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations. Mycoses 2015;58(9):565-71. https://doi.org/10.1111/myc.12357
- Pagano L, Stamouli M, Tumbarello M, et al. Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry. Br J Haematol 2015;170(3):434-9. https://doi.org/10.1111/bjh.13308
- Muhlemann K, Wenger C, Zenhuusern R, et al. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia 2005;19(4):545-50. https://doi.org/10.1038/sj.leu.2403674
- Doring M, Cabanillas KM, Queudeville M, et al. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation. J Cancer Res Clin Oncol 2017;143(7):1281-92. https://doi.org/10.1007/s00432-017-2369-7
- Gwee A, Cranswick N, Cranswick N, et al. Posaconazole: Promising but Problematic in Practice in Pediatric Patients. The Pediatr Infect Dis J 2015;34(6):604-6. https://doi.org/10.1097/INF.0000000000000635
- Gross BN, Ihorst G, Jung M, et al. Posaconazole Therapeutic Drug Monitoring in the Real-life Setting. Pharmacotherapy 2013;33(10): 1117-25. https://doi.org/10.1002/phar.1328
- Doring M, Eikemeier M, Cabanillas KM, et al. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia. Eur J Clin Microbiol Infect Dis 2015;34(6):1189-200. https://doi.org/10.1007/s10096-015-2340-y